ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2019

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.

Mafalda Ramos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.